Somasundaram and colleagues (14) identified that co-localization of FOXP3+ Tregs and MCs in melanoma was correlated with resistance to anti-PD1 therapy and the efficacy of anti-PD1 therapy was improved by depleting MC using the MC inhibitors sunitinib and imatinib. This evidence concerns the gene FOXP3 and melanoma.